Oscar Health, Inc. is a U.S. health insurance and healthcare technology company that offers individual, family, and small group health plans. It also provides technology platforms (e.g., +Oscar) for insurers and payors. The company is focused on integrating digital tools into insurance operations to improve member experience and care management.

CEO: Mark Bertolini

Founded: 2012

Exchange: NYSE

Ticker: OSCR

Website: hioscar.com

Oscar Health - Fundamentals and quantitative valuation scenarios — Oscar Health – Trading View

🧮 Fundamentals & Financial Health

Revenue & Growth

Oscar Health has shown strong top-line growth, with TTM revenue around $11 B+, up ~40%+ year-over-year.
Membership growth is robust, with ~2 M members and ~40% growth, indicating solid market demand.

Profitability

The company remains unprofitable on a net income basis, with a recent TTM net loss around -$244 M.
EPS is negative (no conventional P/E ratio), and margins are thin or negative—typical but still a risk in health insurance.

Cash Flow

Operating and free cash flow have been positive in recent reports, driven by insurance “float” (premiums collected before claims paid).
A strong cash position (~$4B+ including investments) provides runway for growth and strategy execution.

Balance Sheet & Ratios

Strengths

Debt levels are modest, with a manageable debt/equity ratio in many analyses.
Cash and liquid investments provide substantial liquidity.

Weaknesses

Liquidity ratios (e.g., current ratio ~0.9) imply tighter short-term coverage.
Profitability ratios like ROE and ROA remain negative, reflecting losses and asset inefficiency.

Summary: The balance sheet is financially stable, but profitability metrics are currently weak. Growth comes at the expense of earnings, a common pattern in early-stage disruptors.

🧠 Business Model & Strategy

Core model: Health insurance provider using a technology-driven platform to improve member engagement and reduce costs relative to traditional insurers.
Insurance “float” benefits: Oscar collects premiums upfront and pays out claims later—creating a natural working capital advantage that can support operations and investment.
Platform revenue opportunity: The +Oscar tech stack and campaign tools create potential recurring revenue beyond premiums, differentiating it slightly from peers.

Risks:

The health insurance space is highly regulated and policy-dependent, notably on Affordable Care Act (ACA) dynamics. Changes in subsidies or regulation can materially impact economics.
Insurance is highly competitive against giants (UnitedHealth, Elevance), with potential pricing and network disadvantages. Independent insurers are often constrained by scale.

💼 Management & Execution

CEO Mark Bertolini brings industry and operational experience, focusing recently on cost discipline and sustainable growth.
Leadership has sought to balance member growth with underwriting improvements and pricing strategy adjustments. These efforts aim to bend the profitability curve over time.

Recent strategic moves:

Efforts to control medical loss ratios (MLRs) and SG&A costs to work toward profitability.

🛡 Competitive Edge & Moat

Potential Advantages

Digital-first approach: Focus on member experience and tech platforms can lead to retention and operational efficiency.
Targeted market niche: ACA marketplace focus can benefit from favorable policy moves, such as subsidy extensions.

Challenges

Scale matters: incumbents have broader networks and market power, which could limit Oscar’s pricing and market share growth.
The technology edge is not a wide moat: rivals also invest heavily in tech.

📊 Valuation & Market Sentiment

OSCR trades at low multiples versus broader indices due to unprofitability (e.g., low price-to-sales).
Analysts have mixed views, with some upgrades (e.g., Piper Sandler overweight) but average price targets modestly above current levels.
Volatility is higher than the market (beta >1), indicating sensitivity to sentiment and sector news.

📈 Long-Term Potential & Outlook

Bullish Case

Scale economics could eventually turn margins positive, especially if membership growth continues and medical loss ratios stabilize.
Continued tech platform monetization and operational efficiency improvements could expand profitability.
Policy support (ACA subsidies) can shore up demand and pricing.

Bearish Case

Continued lack of profitability and regulatory risk could dampen valuation.
Competitive pressure from major insurers could compress margins or slow member growth.

📌 Summary Evaluation

Component	Assessment
Fundamentals	Strong revenue growth but weak profitability
Financial Health	Solid balance sheet, liquidity adequate
Business Model	Innovative but in a competitive, regulated sector
Management	Experienced, shifting towards discipline
Competitive Edge	Tech advantage, but narrow moat
Valuation	Low multiples, mixed analyst views
Long-Term Potential	Conditional on scaling profitably

🔍 Final Verdict

Oscar Health ($OSCR) is a compelling growth stock with clear strengths in top-line expansion and technology integration, but it currently faces profitability and competitive challenges. Its long-term success depends on achieving sustainable earnings, navigating policy risk, and defending its market position against larger insurers. Investors should balance the growth story against execution risk and valuation uncertainty.

Next are quantitative valuation scenarios for Oscar Health, Inc. ($OSCR) — bull, base, and bear — complete with price targets and underlying assumptions grounded in analyst forecasts, company guidance, and realistic financial expectations. 🙌

📊 Valuation Scenarios for $OSCR

Scenario	Price Target	Upside/Downside vs Current (~$15)	Key Assumptions
Bull Case	$25–$30	+66% to +100%	Strong membership growth, margin improvement, return to profitability, favorable ACA policy tailwinds, multiple expansion supported by improving earnings
Base Case	$14–$18	–7% to +20%	Modest growth with operational losses narrowing, mixed analyst sentiment, price target near consensus
Bear Case	$8–$11	–45% to –27%	Continued losses, deteriorating medical loss ratios, regulatory headwinds, compression of investor sentiment and valuation multiples

🟢 Bull Case: $25–$30

Target Range: $25 to $30 per share

Key Assumptions

Oscar returns to consistent profitability by 2026 or 2027, supported by improving underwriting results and scale benefits from membership growth (guidance suggests potential operating earnings improvements).
Medicare Advantage & Individual market growth expands faster than peers, boosting revenue well above $12–13B by 2027.
Management successfully controls medical loss ratios and SG&A, delivering positive EBITDA annually.
ACA subsidies extended or stabilized, reducing enrollment uncertainty and supporting premium pricing.
Sentiment shift with more buy/overweight ratings and multiple expansion toward ~2.0–3.0× sales or a normalized P/E as profitability stabilizes.
The Piper Sandler bullish price target of $25 (or even $28 historically) supports this upper range.

Valuation Logic

With eventual positive earnings, a normalized P/E of 15–20 could apply.
Example: If EPS reaches ~$1.50–$2.00 by 2027, then P/E 15–20 yields $22.50–$40+.
Strong growth narrative and tech-enabled model could command premium multiples vs traditional insurers if profitability is clear.

🔵 Base Case: $14–$18

Target Range: $14 to $18 per share

Key Assumptions

Company grows revenue steadily (e.g., toward $13–$14B over next 12–18 months) but operates near break-even rather than strong profits.
Mixed analyst sentiment persists (average price targets cluster ~$15–$16).
Market keeps valuation multiples subdued due to continued earnings uncertainty.
Operational improvements occur but not enough to justify a premium valuation.

Valuation Logic

Without meaningful earnings, valuation likely remains tied to revenue multiples (e.g., ~1.0× forward sales) or moderate EV/EBITDA multiples if EBITDA turns positive.
Consensus price targets averaging ~$15–$16 imply this base range.
Stock trading near $15 in this scenario reflects the market’s view that future earnings remain uncertain.

🔴 Bear Case: $8–$11

Target Range: $8 to $11 per share

Key Assumptions

Oscar fails to narrow losses meaningfully, or medical loss ratios worsen materially, leading to structural profitability concerns.
Regulatory or ACA subsidy uncertainty persists, resulting in weaker enrollment retention or pricing pressures.
Analysts cut valuations further if earnings estimates slip. Recent low price targets have fallen to the $8–$11 range from major firms.
Market re-rates the uninsured or loss-making model closer to peers of unprofitable insurers, compressing multiples.

Valuation Logic

If forward earnings remain deeply negative and no clear path to profitability emerges, multiples compress sharply.
A distressed or highly discounted multiple on revenue or EBITDA could anchor price near or below the low end of analyst forecasts.

📈 Quantitative Summary

📍 Bull

Price Target: $25–$30
Rationale: Return to profitability, ACA tailwinds, membership growth, multiple expansion

📍 Base

Price Target: $14–$18
Rationale: Moderate growth, operating near breakeven, market consensus pricing

📍 Bear

Price Target: $8–$11
Rationale: Continued losses, regulatory headwinds, valuation contraction

📌 Final Notes for Investors

Analyst expectations vary widely, from bearish $8 targets to bullish $25+ forecasts — highlighting high uncertainty and volatility risk.
Oscar’s earnings trajectory and ACA policy outcomes will be major determinants of which scenario unfolds.
If Oscar can turn sustainable profits and broaden its tech platform revenue, the valuation could shift toward the bullish rate.
If losses persist or regulatory pressures intensify, the stock could remain in lower valuation territory.

Below is a Discounted Cash Flow (DCF) valuation model for Oscar Health, Inc. (NYSE: OSCR) to estimate its intrinsic equity value per share using explicit revenue, margin, and discount rate assumptions. The model includes a projection period (2025–2029) and a terminal value beyond that, using a reasonable discount rate based on market data. 📊

📌 Oscar Health DCF Valuation Model

📈 Forecast Assumptions (2025–2029)

Revenue Growth

2025 revenue ~ $12.1 B (midpoint of guidance)
Assume 25% CAGR for 2026–2029, reflecting continued membership expansion and premium growth (historical growth >25%–40%+).

Year	Revenue ($B)	CAGR
2025	12.1	—
2026	15.1	+25%
2027	18.9	+25%
2028	23.6	+25%
2029	29.5	+25%

Profitability & Cash Flow Margins

Health insurers’ free cash flows depend on underwriting results and operating efficiency. Given Oscar’s ongoing path to profitability with guided losses narrowing in 2025, we assume:

2025 Free Cash Flow (FCF) negative or marginal — treating 2025 as breakeven for simplicity.
FCF margin ramping to ~3.0% of revenue by 2029, reflecting scale economies and cost discipline.
This parallels models on similar insurers and public DCF templates.

Year	FCF Margin	FCF ($B)
2025	0.0%	0.0
2026	0.5%	0.075
2027	1.0%	0.189
2028	2.0%	0.472
2029	3.0%	0.885

📉 Discount Rate and Terminal Growth

Discount Rate (WACC)

WACC: ≈9.55%, representing cost of capital accounting for equity and debt costs for Oscar Health.

Terminal Growth Rate

3.0% — modest long-term growth reflecting healthcare inflation and market saturation.

📊 Present Value (PV) of FCF

We discount each year’s FCF back to present value:

Year	FCF ($B)	PV Factor (9.55%)	PV of FCF ($B)
2025	0.00	0.912	0.000
2026	0.075	0.833	0.062
2027	0.189	0.760	0.144
2028	0.472	0.693	0.327
2029	0.885	0.631	0.558

**Sum of PV (2025–2029): ~** $1.09 B

📈 Terminal Value

Terminal Value (TV) at 2029 = FCF_2029 × (1 + g) / (WACC – g)

= 0.885 B × 1.03 / (9.55% – 3.0%)

= 0.911 B / 6.55%

≈ $13.91 B

Discounted back to present:

13.91 × 0.631 = ≈ $8.78 B

📌 Enterprise Value & Equity Value

Enterprise Value

PV of forecast FCF: ≈ $1.09 B
PV of Terminal Value: ≈ $8.78 B

Total Enterprise Value ≈ $9.87 B

Adjust for Cash and Debt

Add cash & equivalents: ~$2.15 B (recent estimate)
Subtract total debt: ~$0.69 B

Equity Value ≈ 9.87 + 2.15 – 0.69 = $11.33 B

🧮 Intrinsic Value per Share

If shares outstanding ≈ 260 M:

Intrinsic Value per Share ≈ $11.33 B / 260 M ≈ ~$43.60

📌 DCF Summary & Interpretation

Metric	Value
Discount Rate (WACC)	~9.55%
Terminal Growth Rate	3.0%
PV of 2025–2029 FCF	~$1.09 B
PV of Terminal Value	~$8.78 B
Enterprise Value	~$9.87 B
Equity Value	~$11.33 B
Intrinsic Value per Share	~$43.60

📌 Key Notes & Sensitivities

1) Aggressive Growth Assumptions:

The model assumes ~25% revenue growth through 2029 — high relative to large insurers but supported by Oscar’s historical CAGR and membership expansion.

2) Profitability Ramp:

We assume FCF margins improve materially as underwriting stabilizes and SG&A efficiencies deepen — which is plausible if Oscar meets its 2026 profit guidance.

3) Discount Rate:

A 9.55% WACC reflects risk in health insurance and typical small-cap volatility. A higher rate (e.g., 11–12%) would lower intrinsic value; a lower rate raises it.

4) Terminal Value Sensitivity:

Terminal growth and discount rate significantly impact valuation — small changes here change intrinsic value by 10–30%.

🧠 Conclusion

The DCF model, based on optimistic but structured assumptions, yields an intrinsic value near ~$43.60 per share, suggesting OSCR could be materially undervalued at typical current prices (~$15–$18). However:

This outcome hinges on Oscar Health achieving sustainable profits and free cash flow, which is not yet certain.
Slower growth, lower margins, or regulatory headwinds would materially compress value.

ℹ️ Sources

Below is a clean, organized list of relevant links and sources referenced or conceptually used throughout this analysis of Oscar Health ($OSCR). These cover fundamentals, financials, analyst forecasts, valuation tools, and investor relations.